Suven Life Sciences Ltd
Mr. M Gopalakrishna, is a retired IAS officer and holds a Graduate degree in the Sciences and Law.
Joined the Indian Administrative Services (IAS) in 1962, he worked with the Governments of Assam, Andhra Pradesh and Government of India. In 1997 he superannuated services as Chairman of Rural Electrification Corporation in the rank of Secretary to the Govt. of India.
During his eventful tenure, he was also Chairman, SCOPE, [the Standing Conference of Public Enterprises under the aegis of the Government of India. He has also been Director on several Industrial Promotion and Development Corporations and Manufacturing companies in the Government of India, Government of A.P. and Government of Assam.
With a career spanning nearly over 5 decades, Mr. M. Gopalakrishna adorns the Suven board with his vast administrative, corporate and managerial experience in Public Sector entities in the areas of promotion, development and regulation of industry and power utilities.
This person is not in the org chart
This person is not in any offices
Suven Life Sciences Ltd
1 followers
Suven Life Sciences Limited is a bio-pharmaceutical company. The Company is engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company's segments include Manufacturing (CRAMS), which develops and produces bulk drugs and intermediates under contract manufacturing services; Services (DDDSS), which consists of collaborative research projects (CRP), clinical trials, and testing and analysis services, and Research and Development. Its products consist of active pharmaceutical ingredients (APIs), including Aripiprazole, Armodafinil, Calcium Acetate, Carprofen, Deferasirox, Doxofylline, Entacapone, Fenoprofen Calcium, Rosuvastatin Calcium, Sitagliptin Phosphate and Solifenacin succinate, and intermediates, including 2-nitro phenyl acetic acid and 3, 4-dichlorobenzylamine. The Company is engaged in the drug discovery specializing in central nervous system (CNS)-based programs with over four of the molecules in pipeline under clinical phase of development.